Taiwan Local News

ZUTEC HOLDING AB: CHANGE OF CERTIFIED ADVISER TO MANGOLD FONDKOMMISSION

June 29, 2018

Fri, Jun 29, 2018 17:05 CET Zutec Holding AB has signed an agreement with Mangold Fondkommission regarding the service Certified Adviser. Mangold Fondkommission AB will assume the position as Certified Adviser starting July 1st, 2018. Until then Remium will carry on their duties as the company’s Certified Adviser For more information, please contact: Brendan O’Riordan CEO of Zutec Holding AB; [email protected] Tel: +353 1 2013565E-mail: [email protected] About Zutec Holding AB Zutec develops and markets cloud-based software solutions, primarily directed to companies within the building and construction industry. The Company’s products help clients to increase...

#18-1131 Correction #18-1111 Listing of instrument issued by SG Issuer

June 29, 2018

Fri, Jun 29, 2018 17:00 CET The Issuer has changed the maturity date. Correct information can be found in attached file. As from July 02, 2018, 1 instrument issued by SG Issuer will be listed on NDX Structured Products Sweden. The instrument will be registered at Euroclear Sweden AB. Issuer: SG Issuer Agent: EXCEED For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at [email protected] Nordic Growth Market NGM AB About...

Best California Inns for Exploring Nature

June 29, 2018

Fri, Jun 29, 2018 17:00 CET SACRAMENTO, CA [June 29, 2018]—Grab a pair of binoculars and book a stay at a California bed and breakfast inn, where nature often beckons just outside the door. The California Association of Boutique & Breakfast Inns (CABBI) has compiled a list of inns that are close to trails and waterways teaming with flora and fauna.  At the end of the day, these inns stand ready to welcome guests back with warm hospitality and luxurious appointments. In San Francisco, Presidio National Park is a green oasis encompassing close to 1,500 acres of wildflowers, watersheds, and wildlife. The Inn...

DNB ASA – Share buy-back status after week 26

June 29, 2018

Fri, Jun 29, 2018 16:52 CET During week 26 2018, DNB ASA has purchased 1 013 000 own shares at an average price of NOK 157.78 per share. After this, DNB ASA owns a total of 4 113 000 own shares, in addition to the shares that will be deleted upon completion of the capital reduction resolved in connection with the share buy-back carried out prior to the annual general meeting in 2018. The repurchase of shares is part of the share buy-back programme announced by DNB ASA on 6 June 2018. The buy-back programme comprises up to approximately 24.1 million shares, of which up to approximately 15.9 million shares may be repurchased in the open market. The rest will be redeemed from the state of Norway on a proportionate basis, subject to approval from DNB ASA's annual general meeting in 2019, so that its current ownership interest of 34.00%...

Change in the number of shares and votes in Starbreeze

June 29, 2018

Fri, Jun 29, 2018 16:45 CET STOCKHOLM, SWEDEN (29 June 2018) – Starbreeze AB today announces that the number of Class B shares increased by 1,231,650 during June due to stock options being redeemed. The number of votes increased by 1,231,650.  During June 811,008 employee stock options were redeemed to 1,231,650Class B shares in the company's employee stock option program 2014/2018. Information...

Paying for College: Students are saving more and parents less, and both worry about family emergencies that could lead to withdrawal

June 29, 2018

Fri, Jun 29, 2018 16:40 CET Second Annual Allianz Tuition Insurance College Confidence Index finds a generation gap between students and parents RICHMOND, VA. – Prospective and current college students are ramping up their college savings this year while parents’ savings are on the decline. Further, while students and parents agree that they worry most about a family emergency causing a student to withdraw, students were far more likely than parents to be concerned about an unexpected change in finances as the cause of the emergency. At the same time, parents are less confident than just a year ago in their children’s ability to finish college without needing to withdraw at least temporarily. The...

Change in the number of shares and votes in Camurus AB

June 29, 2018

Fri, Jun 29, 2018 16:30 CET Lund, Sweden — 29 June 2018 — Camurus AB (publ) (Nasdaq Stockholm: CAMX) today announced that the company’s total number of shares as per 29 June 2018 amounts to 38,381,486 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of 1,100,000 shares to Swedish and international investors announced on 29 June 2018. About Camurus Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies...

Oncology Venture looks forward to publishing a clinical update on July 2

June 29, 2018

Fri, Jun 29, 2018 16:30 CET Hoersholm, Denmark, June 29, 2018 – Oncology Venture Sweden AB (OV:ST) and Medical Prognosis Institute A/S (MPI:ST) intends, on a quarterly basis, to publish clinical updates regarding the company’s ongoing projects and activities. Oncology Venture looks forward to publishing the first of these updates through a press release on Monday  July 2, 2018 after 12 o’clock. For further information, please contact   Ulla Hald Buhl, COO...

The divestment of UC finalised

June 29, 2018

...

Bydureon receives positive CHMP opinion for BCise

June 29, 2018

Fri, Jun 29, 2018 16:00 CET 29 June 2018 15:00 BST Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes New formulation of once-weekly Bydureon in a pre-filled device recommended to help improve glycaemic control    AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing...

Latest Press Releases